Abstract
The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.
Original language | English (US) |
---|---|
Pages (from-to) | S1-S29 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 9 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - 2011 |
Keywords
- Molecular targeted therapy
- NCCN
- Patient outcomes
- Renal cell carcinoma
- TKI
- VEGF
- mTOR
ASJC Scopus subject areas
- Oncology